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ABSTRACT  
   Haemophilia is a disorder of coagulation. Haemophilia A is due to deficiency of 
clotting factor VIII and haemophilia B is due to deficiency of factor IX. Both are 
inherited as X-linked, so males usually exhibit the disease and females are carriers. 
Prevalence of haemophilia A is 1 in 5,000 to 10,000 male births and that of 
haemophilia B is 1 in 20,000 to 34,000 births. Haemophilia A accounts for about 
80% cases of haemophilia and haemophilia B around 20%. Arthropathy is a 
common and debilitating complication of haemophilia. If detected earlier 
progression of disease process can be arrested by effective management.                                                                           
METHODS 
 Here 40 patients with haemophilia are studied and their indications of 
admissions were noted. They were assessed clinically as well as radiologically for 
the detection of arthropathy  irrespective of  whether they were admitted for 
musculoskeletal bleeds or not. 
RESULTS   
 Majority of patients were admitted with musculoskeletal bleeds(29 of 40). 
Most of the patients were haemophilia A patients(34 of 40). Family history was 
present in only 10% cases. Majority of patients(23 of 40) were in stage III of 
haemophilic arthropathy as staged according to Arnold hilgartner classification. 
Out of 11 patients admitted with non musculoskeletal bleeds only one had clinical 
evidence of arthropathy and out of the remaining  10 patients 4 were already in 
stage III of haemophilic arthropathy without any symptoms and signs. Arthropathy 
worsens as the duration of disease process  increases. 
CONCLUSIONS 
Haemophilia is a common coagulation disorder encountered by physicians. The 
most common indication for admissions are musculoskeletal bleeds and knee being 
the commonest joint involved. As the duration of disease process increases the risk 
of permanent joint damage also goes on the increase. Those patients with early 
stages of arthropathy are treated conservatively with factor replacement therapy to 
halt the progression of disease. If not treated adequately, due to chronic synovitis 
permanent joint damage occurs. Once this happens only surgical cure is possible to 
restore the joint function. The various modalities available are synovectomy, 
arthroplasty and joint replacement in severe cases. 
Even in haemophilics admitted for non-musculoskeletal indications arthropathy 
may lie undetected and if unnoticed can result in joint damage. 
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INTRODUCTION 
           
 Haemophilia is a disorder of coagulation. Haemophilia A is due to deficiency of 
clotting factor VIII and haemophilia B is due to deficiency of factor IX. Both are 
inherited as X-linked, so males usually exhibit the disease and females are carriers.  
 
Prevalence of haemophilia A is 1 in 5,000 to 10,000 male births and that of 
haemophilia B is 1 in 20,000 to 34,000 births. Haemophilia A accounts for about 
80% cases of haemophilia and haemophilia B around 20%. Haemophilia C is due 
to deficiency of factor XI and unlike other haemophilias it is autosomal and is also 
the rarest of the three. 
 
Haemophilia lowers blood plasma clotting factor levels of the coagulation factors 
needed for a normal clotting process. Thus when a blood vessel is injured, a 
temporary scab does form, but the missing coagulation factors prevent fibrin 
formation, which is necessary to maintain the blood clot. A haemophiliac does not 
bleed more intensely than a person without it, but can bleed for a much longer 
time. In severe haemophiliacs even a minor injury can result in blood loss lasting 
 8 
days or weeks, or even never healing completely. In areas such as the brain or 
inside joints, this can be fatal or permanently debilitating. 
 
Spontaneous and recurrent haemarthrosis can lead to a deforming arthritis. Chronic 
arthritis can result in restricted joint motion, or laxity with subluxation, features of 
end stage disease. In patients with chronic symptomatic synovial proliferation and 
recurrent haemarthrosis, synovectomy is beneficial rather than conservative 
management useful in early stages of disease. 
So early detection of arthropathy and surgical intervention can improve the quality 
of life of these patients with drastic reduction in both mortality and morbidity. 
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AIM OF STUDY 
 
• To find out the indications for  admission of haemophilia patients 
  
•  Early detection of haemophilic arthropathy, clinically and 
radiologically 
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REVIEW OF LITERATURE 
 
    Haemophilia refers to a group of inherited diseases in which there is a functional 
deficiency of a specific clotting factor. The most common are 
hemophilia A(classic hemophilia)and hemophilia B (Christmas disease); the 
deficient factors are factor VIII (hemophilia A) and factor IX (hemophilia B). The 
incidence and severity of hemorrhagic complications of hemophilia are directly 
related to the severity of the underlying coagulation defect. 
    Although the intrinsic pathway of coagulation is severely impaired 
in hemophilia, the extrinsic tissue factor -dependent pathway remains intact 
and is probably the major hemostatic regulatory system. Normal synovial 
tissue and cultures of synovial fibroblasts have been found to be deficient in 
tissue factor, 2 which suggests that in synovium-lined joints, hemophiliacs 
have functional inactivity of intrinsic and extrinsic coagulation pathways. This 
situation may explain the marked propensity toward hemorrhage in joints 
compared with other tissue sites in these patients. 
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CLINICAL FEATURES 
 Distribution of acute haemarthrosis based on a study of 139 patients with 
hemophilia by Steven MM, Yogarojah S, Madhok R, et al: Haemophilic 
arthritis. QJM 58:181, 1986.) 
 
ACUTE HEMARTHROSIS 
Nearly all patients with severe hemophilia A or B (<1% activity of the 
deficient factor) and half of patients with moderate disease activity experience 
haemarthrosis. Acute hemarthroses generally first occur when a child begins to 
walk and continue, usually cyclically, into adulthood, when the frequency 
diminishes. Patients frequently have premonitory symptoms, such as stiffness 
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or warmth in the affected joint, followed by intense pain, which may be due 
partly to rapid joint capsule distention. 
Pain is accompanied by objective clinical findings of warmth, a tense effusion, 
tenderness, limitation of motion, and a joint that is often held in a flexed 
position. Joint pain responds rapidly to replacement of the deficient clotting 
factor. If hemostasis is achieved early after onset of haemarthrosis, full joint 
function may be regained within 12 to 24 hours. If the hemorrhage is more 
advanced, however, blood is resorbed slowly over 5 to 7 days, and full joint 
function is regained within 10 to 14 days. 
 
SUBACUTE OR CHRONIC ARTHRITIS 
Recurrent hemarthroses, particularly in patients with severe factor deficiency, 
may lead to a self-perpetuating condition in which joint abnormalities persist 
in intervals between bleeding episodes. The involved joint is chronically 
swollen, although painless and only slightly warm. Chronic synovitis, 
including prominent synovial proliferation with or without effusion, may be 
present. There may be mild limitation of motion, often with a flexion 
deformity. Factor replacement does not modify these findings. 
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 Radiographic changes of hemophilic 
arthropathy. A, Early arthritis of the knee, 
showing soft tissue swelling, widening of 
the femoral condyles and tibial plateau, 
irregularity of the distal femoral epiphysis, 
and a few subchondral bone cysts. B, More 
advanced arthritis involving the elbow, 
showing almost complete loss of joint space 
and extensive subchondral cyst formation. 
The widening of the proximal radius is 
characteristic of hemophilic arthropathy. 
  
 
 
END-STAGE HEMOPHILIC ARTHROPATHY 
Long-standing end-stage hemophilic arthropathy has features in common with 
degenerative joint disease and advanced rheumatoid arthritis. The joint appears 
enlarged and “knobby,” owing to osteophytic bone overgrowth. Synovial 
thickening and effusion are not prominent, however. Range of motion is 
severely restricted, and fibrous ankylosis is common. Subluxation, joint laxity, 
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and malalignment are frequently present. Hemarthroses decrease in frequency, 
however.  
 
 
SEPTIC ARTHRITIS 
Until the early 1980s, septic arthritis rarely occurred in hemophiliac patients. 
With the widespread occurrence of human immunodeficiency virus (HIV) 
infection as a result of contaminated factor concentrates, the incidence of this 
complication has increased significantly.3,4 Septic arthritis is seen more often 
in adult than in pediatric hemophiliacs and is most commonly monoarticular, 
usually involving the knee. In contrast to spontaneous haemarthrosis, septic 
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arthritis is significantly associated with a temperature greater than 38oC within 
12 hours of presentation and articular pain that does not improve with 
replacement therapy.3 Peripheral leukocyte count may not be elevated, 
particularly in HIV-positive patients.5 A predisposing factor other than 
hemophilic arthropathy is often identifiable, including previous arthrocentesis 
or arthroplasty, intravenous drug use, and infected indwelling venous access 
catheters. Staphylococcus aureus is the most frequently identified organism 
even in HIV-infected patients, followed by Streptococcus pneumoniae.5 
MUSCLE AND SOFT TISSUE HEMORRHAGE 
Bleeding into muscles and soft tissue is common in hemophiliacs and may be 
more insidious than haemarthrosis because of the lack of premonitory 
symptoms. Bleeding into the iliopsoas and gastrocnemius muscles and the 
forearm results in well-described syndromes with which the rheumatologist 
should be familiar. Iliopsoas hemorrhage produces acute groin pain with 
marked pain on hip extension and a hip flexion contracture. Rotation is 
preserved, in contrast to intra-articular hemorrhage. If untreated, the expanding 
soft tissue mass may compress the femoral nerve, causing signs and symptoms 
of femoral neuropathy.6, 7 Bleeding into the gastrocnemius muscle can cause an 
equinus deformity from heel cord contracture.6 Finally, hemorrhage into 
closed compartments can cause acute muscle necrosis and nerve 
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compression.8 Of particular importance is bleeding into the volar compartment 
of the forearm, which can cause flexion deformities of the wrist and fingers. If 
a compartment syndrome is suspected, compartment pressures should be 
measured to confirm the diagnosis. 
A large intramuscular hemorrhage uncommonly results in the formation of a 
simple muscle cyst, which clinically appears to be an encapsulated soft tissue 
area of swelling overlying muscle. Cyst formation in this setting is confined by 
the muscular fascial plane and most likely results from inadequate resorption 
of blood and clot. Subperiosteal or intraosseous hemorrhage, in contrast, may 
lead to a pseudotumor, a rare skeletal complication of hemophilia. Hemophilic 
pseudotumors are of two types: the adult type, which occurs proximally, 
usually in the pelvis or femur; and the childhood type, which occurs distal to 
the elbows or knees and carries a better prognosis.9, 10 
Conservative early management of muscle cysts and childhood-type 
pseudotumors is indicated, including immobilization and factor replacement. 
In adult-type pseudotumors, which are usually refractory to conservative 
therapy, and in progressive childhood pseudotumors, surgical removal is 
indicated9 to prevent serious complications, such as spontaneous rupture, 
fistula formation, neurologic or vascular entrapment, and fracture of adjacent 
bone. Aspiration of a pseudotumor or cyst is contraindicated. 
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DIAGNOSTIC IMAGING 
RADIOGRAPHS 
The earliest radiographic changes in hemophilic arthropathy are confined to 
the soft tissue and reflect acute haemarthrosis. The joint capsule is distended 
with displacement of fat pads, and there is an increased hazy density caused by 
intra-articular blood. Haemarthrosis before epiphyseal plate closure may result 
in epiphyseal overgrowth and irregularity. Occasionally, premature epiphyseal 
closure is seen. 
With the progression of chronic proliferative synovitis, irreversible radiologic 
changes appear.11 these changes reflect the inflammatory and the degenerative 
nature of chronic hemophilic arthropathy. A study of serial radiographs of 
symptomatic joints in hemophilic patients suggests that serial scoring with 
conventionally accepted techniques may be a cost-effective alternative to 
magnetic resonance imaging (MRI) in predicting progressive synovial 
hypertrophy.12 
 
Radiologic Manifestations of Chronic Hemophilic Arthropathy 
Characteristic Also Seen in 
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Characteristic Also Seen in 
Periarticular soft tissue swelling RA 
Periarticular demineralization RA 
Marginal erosions RA 
Subchondral irregularity and cyst formation RA, OA 
Decreased joint space OA 
Osteophyte formation CPPD[∗] 
Chondrocalcinosis   
Specific 
    Femoral intercondylar notch widening 
    Squaring of distal patellar margin (lateral view) 
    Proximal radial enlargement 
    Talar flattening? ankle ankylosis[†] 
 
  
CPPD, calcium pyrophosphate deposition disease; OA, osteoarthritis; RA, 
rheumatoid arthritis. 
 
 From Jensen PS, Putnam CE: Chondrocalcinosis and hemophilia. Clin Radiol 
28:401, 1977. 
† From Schreiber RR: Musculoskeletal system: Radiologic findings. In Brinkhous 
KM, Hemker HC (eds): Handbook of Hemophilia, I. New York, American 
Elsevier, 1975. 
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OTHER IMAGING METHODS 
MRI is now routinely used to stage hemophilic arthritis accurately to determine 
optimal treatment and to follow response to therapy.13A scoring system based on 
MRI has been proposed.14 Additionally, MRI and ultrasonography are useful in the 
detection and the quantitation of soft tissue bleeding, cysts, and pseudotumors.  
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MRI image in a patient with hemophilic arthropathy shows dark, synovial masses 
that erode the cartilage and produce subchondral cysts  
PATHOLOGIC FEATURES AND PATHOGENESIS 
Pathologic studies of human hemophilic arthropathy have been limited to 
synovial specimens obtained at surgery15, 16 or at postmortem examination and 
reflect changes of advanced disease only. Studies of experimentally produced 
haemarthrosis in animals, 17, 18 post-traumatic haemarthrosis in nonhemophilic 
humans, 19 and canine and murine models of hemophilia A20-22 have provided 
an understanding of the earliest changes induced by acute haemarthrosis and 
their evolution to chronic arthritis. 
As reviewed more recently, 23 the process most likely includes catabolic 
activation of synovial cells by exposure to blood components with subsequent 
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cartilage destruction and a direct destructive effect of intra-articular blood on 
cartilage. A single synovial hemorrhage induces serial changes in the synovial 
membrane, including early focal villous synovial proliferation and subsynovial 
diapedesis of erythrocytes, followed by the appearance of perivascular 
inflammatory cells, patchy subsynovial fibrosis, and intracellular iron 
accumulation in synovial cells and subsynovial macrophages. With repeated 
hemarthroses, the synovium becomes grossly hypertrophied and 
hyperpigmented, with eventual organization into a pannus that invades and 
erodes marginal cartilage. On histologic examination, villous hypertrophy and 
subsynovial fibrosis progress, but inflammatory cells are scarce.16 Seventy-five 
percent of synoviocytes contain siderosomes (electron-dense, iron-filled 
deposits within lysosomes), in contrast to 10% in normal synovium and 25% 
in rheumatoid synovium.24 Iron deposits are associated with the production of 
proinflammatory cytokines and synovial inhibition of the formation of human 
cartilage matrix. Although the inflammatory synovial changes are mild, the 
synovial production of proinflammatory mediators, including interleukin-1 and 
interleukin-6 and tumor necrosis factor-α, approaches that of rheumatoid 
synovium.23 The articular cartilage is grossly and microscopically abnormal in 
the setting of recurrent hemarthrosis.17 There are areas of cartilaginous 
fissuring and rarefaction exposing sclerotic bone. The remaining cartilage is 
 thin and unevenly distributed, often freely protruding into the joint cavity. 
Bone erosions appear at weight
glycosaminoglycan, which also is seen in degenerative arthritis.
 
Current studies suggest that recurrent 
hemophilic arthropathy through direct and indirect effects of iron on the 
synovium24,26 and cartilage,
synovium, and through an alteration in cartilage biochemical composition similar 
to that seen in degenerative arthritis. There may be a relationship between 
haemarthrosis-induced overexpression of oncogenes (e.g.,
the dysregulated, tumor-like pr
 
-bearing surfaces. There is loss of matrix 
16, 25
 
  
 
Figure. Proliferative synovitis of 
hemophilia. Villous hypertrophy of 
synovium with pigment deposition in 
superficial cells. The reaction is mainly 
synovial cell hyperplasia. Infiltrating 
inflammatory cells are scarce 
(Hematoxylin and eosin). 
haemarthrosis induces joint destruction in 
25,27 by the degradative effect of the proliferative 
 c-myc and
oliferation of hemophilic synovium.29, 30
24
 
 
 mdm-2) and 
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DIAGNOSIS 
In most cases of congenital coagulopathy, the diagnosis has been made before 
presentation to a rheumatologist. In the case of hemophilia, if there is an 
affected family member, prenatal diagnosis is possible. Because the 
spontaneous mutation rate in hemophilia is significant, the diagnosis may not 
be suspected until infancy, when recurrent, large ecchymoses or sustained oral 
hemorrhages commonly develop in most affected patients. In the case of 
hemophilia A or hemophilia B, haemarthrosis is usually a later manifestation, 
but it may be the initial symptom of other, less severe coagulopathies, even in 
adulthood. When a coagulopathy is suspected, baseline screening tests, 
including prothrombin time, activated partial thromboplastin time, and platelet 
count, should be performed. In patients with hemophilia, the prothrombin time 
and platelet count are normal, and the activated partial thromboplastin time is 
prolonged, denoting a defect in the intrinsic clotting cascade. Referral to a 
hematologist, who obtains the appropriate factor assays, is the next step. 
Individuals with factor VIII or IX levels of 1% or less of the normal level have 
joint and muscle hemorrhages requiring therapy on an average four or five 
times per month. Such patients are classified as having severe hemophilia. 
Individuals with factor VIII or IX levels greater than 5% of normal are 
considered to have mild hemophilia and usually bleed only with trauma or at 
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surgery. Occasional “spontaneous” haemarthrosis may occur in such patients, 
especially in joints damaged by previously undertreated hemorrhage. 
Patients whose factor VIII or IX levels fall between these two ranges are 
considered to have moderately severe hemophilia, and their clinical picture 
falls somewhere between the extremes. If such patients have had multiple 
untreated or suboptimally treated hemarthroses with subsequent joint damage, 
the anatomic instability of these joints would cause frequent and severe 
bleeding, and the condition would appear clinically more severe than the factor 
VIII or IX assay might suggest. 
TREATMENT OF HEMOPHILIA 
Until recent years, in most hemophilia centers factor replacement therapy has 
been given on demand; that is, factor concentrate has been infused at the 
earliest sign of a hemorrhage. With the introduction of highly purified, safe 
concentrates, prophylactic treatment is now much more common in countries 
where this product is available, especially in pediatric patients.31,32Instead of 
being infused when a hemorrhage has occurred, factor concentrate is given 
regularly three times per week to prevent bleeds. Prophylaxis is started before 
any joint damage has occurred, usually at approximately 2 years of age, with 
the goal of minimizing bleeding episodes to no more than four to six per year. 
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Indwelling catheters, such as Port-A-Cath and Hickman lines, are required for 
factor administration because frequent venipunctures are painful and 
cumbersome. More recent data suggest that the institution of prophylactic 
factor infusion would significantly decrease the long-term joint sequelae of 
hemophilia and decrease lifetime disability.33, 34, 35 
With adequate factor replacement, all types of surgery, including joint 
replacements, can be done. Surgical intervention in a patient with hemophilia 
should be done, however, only at specialized centers with blood bank and 
coagulation laboratory support and with the participation of a hematologist 
who specializes in clotting disorders. A surgeon who feels comfortable 
operating on patients with clotting disorders also is essential. Constant-
infusion techniques for administering factor concentrate during and after 
surgery have made adequate factor levels easier to maintain and have 
decreased overall perioperative use of factor concentrates.36 Many types of 
commercial factor VIII concentrate are available, most of which are 
manufactured with recombinant technology. 
FACTOR VIII REPLACEMENT 
All plasma-derived factor concentrates are virally inactivated by various 
methods, including exposure to solvent detergent, heat, and pasteurization. 
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Recombinant factor VIII concentrates, manufactured by inserting the human 
factor VIII gene into a mammalian cell line, are widely available and used 
almost exclusively, especially in developed countiries.37, 38 Because human 
plasma is not used in their production, transfusion-transmitted diseases, such 
as hepatitis and HIV-1, are no longer a risk. Recombinant concentrates at 
doses similar to those of plasma-derived concentrates have been efficacious in 
the treatment of hemorrhages. Half-life and recovery times for the infused 
factor VIII are similar to those for plasma-derived concentrates. Current prices 
range from $0.35 to $0.90 per unit for factor VIII plasma-derived concentrates 
and from $1.00 to $1.20 per unit for recombinant factor VIII. In most 
hemophilia centers in the United States, recombinant factor concentrates are 
the only concentrates used, although high-purity, plasma-derived concentrates 
are still available. Because these concentrates have made early and intensive 
home therapy possible, overall costs of health care have greatly declined for 
patients treated with these materials. 
Arginine vasopressin (desmopressin), a vasopressin analogue, can be used in 
the treatment of mild hemophilia A to increase the endogenous factor VIII 
level. Desmopressin increases the baseline factor VIII level about threefold, so 
a baseline level of at least 10% is required for efficacy.39Because this is not a 
blood product, it poses no danger of transmitting blood-borne viruses. 
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Although cryoprecipitate contains factor VIII, its use has been discouraged 
because it is not virally inactivated. It is less safe than concentrates. 
FACTOR IX REPLACEMENT 
Factor IX is not found in either cryoprecipitate or factor VIII concentrate; 
these two materials are totally ineffective for the treatment of hemophilia B. 
Fresh-frozen plasma does contain factor IX and has been used in the past. 
Most fresh-frozen plasma products are not virally inactivated and are less safe 
than factor IX concentrates. 
The principles of treatment are similar to those for factor VIII replacement. 
Because the half-life of factor IX is longer, however, it can be given less 
frequently. Demand therapy is still commonly used; as for factor VIII 
deficiency, however, prophylaxis is beginning to be used in pediatric patients. 
Several plasma-derived factor IX concentrates are available, all virally 
inactivated. In the past, all such concentrates also contained factors II, VII, and 
X (prothrombin complex concentrates). Currently, only pure factor IX 
concentrates are used to treat factor IX deficiency. As with factor VIII 
concentrates, a recombinant factor IX concentrate is available and is widely 
used. Recovery is less than that of its plasma-derived counterpart, however, 
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and higher doses (approximately 1.5 times calculated levels) must be infused 
to reach appropriate levels. 
COMPLICATIONS OF FACTOR REPLACEMENT THERAPY 
Inhibitor Antibodies 
Inhibitor antibodies may develop after exposure to factor concentrate. They 
occur most often in patients with severe hemophilia after 9 to 30 exposures of 
replacement therapy, usually before the age of 5 years. There may be a familial 
predisposition to the development of this complication. Because bleeding 
cannot be reliably controlled in patients with inhibitor antibodies, elective 
surgery in these patients should be done only after careful deliberation. 
Inhibitor antibodies in factor VIII–deficient hemophiliacs are IgG antibodies 
(usually IgG4) and may have an unpredictable natural history. Low titer and 
clinically weak antibodies sometimes are easily neutralized by factor VIII and 
do not undergo anamnestic increases in titer after multiple factor VIII 
challenges. Such antibodies may rarely become high in titer. In other patients, 
antibody titers increase after each exposure to factor VIII. Still other patients 
seem to lose antibody spontaneously despite multiple subsequent factor VIII 
challenges. The type of antibody response to factor VIII infusion and the 
patient’s clinical response dictate therapy. 
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Therapy for patients with inhibitor antibodies have been reviewed more 
recently.40 Induction of immune tolerance through frequent administration of 
factor VIII successfully eliminates inhibitors in 80% of patients. In patients in 
whom immune tolerance therapy is unsuccessful, there are several approaches 
for management of acute bleeding episodes, including the administration of 
activated prothrombin complex concentrate or, more recently, recombinant 
activated factor VIIa (rVIIa, Novo-Seven; Novo Nordisk, Bagsvaerd, 
Denmark). rVIIa is thought to function directly at the site of injury, causing 
activation of factor IX and the extrinsic clotting system locally. Porcine factor 
VIII, which has limited cross-reactivity with the human antibody, was used 
previously, but has been removed from the market because of contamination 
with porcine parvovirus. A recombinant form of this protein is being 
investigated. 
The use of immunosuppressives or glucocorticoids has been abandoned in 
most centers owing to lack of efficacy in this condition and serious side 
effects. Regimens of regular factor VIII infusions for induction of tolerance 
have been successful in eliminating the antibody. It has been suggested by 
some groups that an immune tolerance regimen be started as early as possible 
after an inhibitor develops. Rituximab may be useful to suppress inhibitor 
titers in refractory patients.41 
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Inhibitor antibodies against factor IX are exceedingly rare. There is no 
generally accepted efficacious therapy. Treatment usually includes large and 
frequent doses of factor IX concentrate. Induction of immune tolerance with 
elimination of the antibody also has been used, but with less success than with 
antibodies to factor VIII. Using large doses of purified factor IX concentrate in 
some patients with inhibitor antibodies to factor IX has resulted in 
anaphylactic reactions and nephrotic syndrome secondary to immune complex 
formation and deposition in the kidney.42, 43 
Human Immunodeficiency Virus 
HIV was introduced into the U.S. blood supply in the 1970s. By the late 
1970s, factor concentrate was widely contaminated. By 1982, approximately 
50% of patients with hemophilia were infected with HIV.44 Currently; 
approximately 10% to 20% of American hemophiliacs are infected with HIV. 
As with other infected individuals, CD4+ lymphocyte counts and HIV titers are 
used to guide treatment regimens. Since 1985, in the manufacture of plasma-
derived concentrates a triple barrier to viral contamination of plasma-derived 
concentrates has been employed: (1) self exclusion for donors, (2) donor 
screening with serologic tests for HIV, and (3) viral inactivation during 
concentrate production. Recombinant concentrates also are now widely 
 33
available. Acquisition of HIV-1 through factor concentrate in patients with 
hemophilia has been virtually nonexistent since 1985. 
Viral Hepatitis 
A second infectious side effect of either cryoprecipitate or factor concentrate is 
hepatitis, which may be a result of parenterally transmitted hepatitis A, B, C, 
or G virus; cytomegalovirus; or other as yet unidentified pathogens. In most 
series, most patients with hemophilia treated before the 1980s have plasma 
levels of hepatitis B virus surface antibody, and a few (2% to 5%) carry 
hepatitis B virus surface antigen. Approximately 80% of hemophiliacs 
transfused before 1990 have antibody to hepatitis C virus, 45 which, in contrast 
to hepatitis B virus antibody, is a marker for ongoing infection. Virucidal 
concentrate treatment methods have reduced, but not eliminated, parenteral 
transmission of hepatitis B and C viruses. Transmission of hepatitis A and G 
viruses also has been reported with the use of plasma-derived concentrates. 
Vaccination against hepatitis B and hepatitis A is now recommended for 
infants with hemophilia. Transmission of hepatitis has decreased dramatically 
because almost all pediatric patients are treated with recombinant products. 
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THERAPY FOR MUSCULOSKELETAL COMPLICATIONS OF 
HEMOPHILIA 
Acute Haemarthrosis 
The most important measure in therapy for acute haemarthrosis is prompt 
correction of the clotting abnormality by administration of the deficient factor. 
Arthrocentesis, if it is accomplished within 24 hours of the onset of symptoms 
(but after factor replacement), may be symptomatically beneficial in advanced 
acute haemarthrosis; however, for diagnostic and potentially therapeutic 
purposes, it should be considered mandatory at any time if suspicion of 
infection is high.4, 7 Analgesia and brief joint immobilization for no more than 
2 days often aid in pain control. Subsequently, passive range-of-motion 
isometric exercise should be initiated to reduce the likelihood of joint 
contracture. 
 
 
 
 
    Algorithm of acute arthritis in hemophilia.
 
Chronic Hemophilic Arthropathy
Conservative 
A variety of conservative measures can bring remarkable benefit in the setting 
of chronic hemophilic arthropathy,
    Prophylactic factor infusions
    Intensive physical therapy for muscle building and increased joint 
 
 
 
 46 -49 including the following: 
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stability 
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    Periods of avoidance of weight bearing to allow regression of synovitis 
    Correction of flexion contractures by wedging casts, night splints, or the 
judicious use of traction 
    Training in sports to allow future maintenance of muscle mass 
 
In modern treatment programs, aspiration of joints with chronic synovial 
effusions is rarely necessary or of lasting benefit. Failure of these conservative 
modalities to relieve symptoms or produce regression of synovitis should 
prompt consideration of other options, including local corticosteroid injections 
(which have been described as useful more recently),50 the use of nonsteroidal 
anti-inflammatory drugs (NSAIDs), synovectomy, and joint replacement in the 
end stage. 
Despite the obvious theoretical contraindications to the use of NSAIDs in 
hemophilia (i.e., the antiplatelet effects), several NSAIDs may be used safely 
for short periods as adjuncts to the conservative regimen. Ibuprofen, salsalate, 
and magnesium salicylate have been shown in a few patients to be safe and 
efficacious in reducing joint pain and analgesic dependence,51,52 although long-
term regression of synovitis and modification of the course of chronic 
hemophilic arthropathy have not been shown with any NSAID. The selective 
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cyclooxygenase-2 inhibitor class of NSAIDs does not have significant 
antiplatelet effects and theoretically should be safer than conventional NSAIDs 
in patients with hemophilia. Rofecoxib and valdecoxib have been withdrawn 
from the market because of a causative link to increased risk of cardiovascular 
events. Although others are in development, celecoxib, the only remaining 
cyclooxygenase-2 inhibitor on the market, has not been specifically tested in 
hemophilic patients and, similar to other NSAIDs, should be used with 
caution. 
Synovectomy 
Synovectomy in the setting of hemophilic arthritis has been shown to reduce 
the incidence of recurrent haemarthrosis and the severity of synovitis. This 
procedure can be accomplished surgically, arthroscopically, or through intra-
articular injections of radioactive colloids. Patients should be considered for 
synovectomy if, despite aggressive conservative measures as outlined 
previously, persistent hemarthroses continue with ongoing chronic synovitis. 
In our center, specific indications for synovectomy include persistence of at 
least two hemarthroses per month in the same joint accompanied by symptoms 
and signs of chronic synovitis despite at least 4 months of conservative 
therapy, including intensive factor replacement. The major drawback to 
surgical synovectomy remains the observation, confirmed in most series, 
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53,54 that joint motion is reduced postoperatively compared with preoperative 
baseline joint motion, despite intensive rehabilitation. 
To overcome this finding and the high cost of hospitalization and factor 
replacement therapy attendant with surgical synovectomy, arthroscopic 
synovectomy has been employed in chronic hemophilic arthritis in recent 
years. Most follow-up series report that this technique is as successful as 
surgical synovectomy and results in less loss of motion,55,56,57 particularly 
when continuous passive motion is used in the postoperative period.58The total 
cost of the procedure is less than that of surgical synovectomy, as is the 
rehabilitation period. Postoperative bleeding after arthroscopic synovectomy 
has been associated with poor results. 
An alternative to surgical or arthroscopic synovectomy is ablation of the 
synovium using either radioisotopic or chemical agents, as reviewed more 
recently.32,59,60 Such a nonoperative approach has been successful in reducing 
bleeding episodes by 70% to 80% in patients with hemophilia61and is 
especially useful in patients with circulating factor inhibitors, in whom surgery 
is relatively contraindicated. Commonly used radioisotopes in the United 
States include colloidal 23P chromic phosphate, yttrium 90, and radioactive 
colloidal gold (198Au). Theoretical long-term carcinogenic and teratogenic 
effects remain the major concerns associated with this technique in patients 
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who may have long life expectancies and are still of reproductive age; these 
effects have limited the use of radioisotopes in the United States, but less so in 
Europe. Chemical synovectomies using osmic acid, rifampicin, and hyaluronic 
acid have been attempted in some European centers with modest success, 
especially in children.59 The short-term results of radioactive and chemical 
synovectomies are similar, although long-term outcomes may be superior in 
radioisotopic synovectomy.32Radioactive and chemical synovectomies remain 
experimental in the United States. Both have the advantages of being 
minimally invasive, requiring little factor replacement, and resulting in little 
morbidity, and both are much less expensive than operative procedures. 
Total Joint Replacement 
Major orthopaedic procedures, including total joint replacements, 62-65 have been 
employed safely and successfully in end-stage hemophilic arthropathy, including 
in patients with inhibitor antibodies.66 The primary indication for total joint 
replacement is pain in an involved joint that is refractory to all conservative 
measures. Careful preoperative planning is imperative, including assessment for 
the presence of inhibitors, planning for factor replacement, and planning for a 
multidisciplinary rehabilitative program.67 It is concerning, however, that most 
hemophilic patients in need of total joint replacement are young and may, if they 
are not infected with HIV, have a long life expectancy. If the procedure is 
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performed at a young age, this virtually ensures the need for one or more revisions 
during the patient’s lifetime. In addition, patients are at increased risk for 
complications of surgery because of their underlying coagulopathy, and loosening 
is observed more commonly than in nonhemophilic patients in long-term follow-
up. These findings suggest that total joint replacement should be reserved for the 
most severe cases of hemophilic arthropathy and deferred as long as possible. A 
comprehensive recent review details the many orthopaedic procedures that are now 
available for alleviating the pain and deformity resulting from hemophilic 
arthropathy.68 
Dosing Regimens for Bleeding and Prophylaxis in Hemophilia 
Site 
Factor 
Level 
Dose 
HemophiliaA 
Dose 
HemophiliaB 
Duration 
of 
Treatment Comments 
Joint 30%–
70% 
15–35 U/kg 30–70 U/kg 1–3 days Splinting 
temporary 
splinting, no 
weight bearing 
Life threatening 
(eg, intracranial, 
retropharyngeal, 
retroperitoneal) 
80%–
100% 
40–50 U/kg 80–100 U/kg 10–14 days Antifibrinolyti
c therapy with 
retropharynge
al bleeds 
Soft tissue 30%–
50% 
15–25 U/kg 30–50 U/kg 2–5 days Higher levels 
can be used 
for 
compartment 
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Site 
Factor 
Level 
Dose 
HemophiliaA 
Dose 
HemophiliaB 
Duration 
of 
Treatment Comments 
syndrome 
Surgery 80%–
100% 
40–50 U/kg 80–100 U/kg 10–14 (or 
shorter for 
minor 
procedures) 
Significant 
blood loss can 
occur into 
large muscles 
of the lower 
extremity and 
the iliopsoas 
Oral 20%–
50% 
10–25 U/kg 20–50 U/kg 1–2 Antifibrinolyti
c therapy 
Gastrointestinal[*] 
30%–
100% 15–50 U/kg 30–100 U/kg 2–3 
Should be 
evaluated for 
source 
Genitourinary[†] 
30%–
50% 15–25 U/kg 30–50 U/kg 1–2 
Avoid 
Antifibrinolyti
c therapy 
Prophylaxis[‡] 50% 25 U/kg 50 U/kg 
qod or 
3?/week 
Steroids may 
be useful 
Data from DiMichele, Lusher, and Mannucci. 
* Depending on severity. 
† Painless spontaneous hematuria often requires no treatment other than fluid 
intake. Persistence requires treatment and evaluation. 
‡ Use of a schedule of 25 U/kg qod and a dose of 40 U/kg with an interval of 2 
days between the next dose may increase compliance by decreasing infusions to 
three per week. 
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MATERIALS AND METHODS 
              This study was done at the haemophilia clinic and the medical wards of 
Coimbatore Medical College. 
Fourty haemophilic patients already diagnosed as per factor assays and registered 
under haemophilic society of India, were included in the study. 
 
INCLUSION CRITERIA 
1. Patients above 15 years of age. 
2. Presence of bleeding manifestations. 
3. Consent of patient available for the study. 
EXCLUSION CRITERIA 
1. Patients less than 15 years of age. 
2. Patients with no bleeding manifestations. 
3. Consent not available. 
SOURCE OF DATA 
40 patients with haemophilia admitted in Coimbatore medical 
college during the study period from June 2010 to October 2011.. 
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Haemophilic patients admitted without any bleeding manifestations were excluded 
from the study. 
An informed consent was taken. The study protocol was approved by the Ethical 
Committee of Coimbatore Medical College Hospital. 
The indications of admissions were noted. Also took a note of patients who had 
earlier admissions and indication of admission, then. 
The patients were then subjected to both clinical and radiological evaluation for the 
early detection of haemophilic arthropathy. 
Patients with no soft tissue and skeletal abnormalities were taken as normal. All 
the patients were then subjected to clinical examination and they were evaluated 
radiologically, either with CT/MRI of the knee joint by a qualified radiologist. 
We used knee joint because it is the most common and earliest joint to get involved 
in haemophilic arthropathy. Haemophilic arthropathy of knee joint was graded as 
per Arnold-hilgartner classification. 
Arnold-Hilgartner classification is a plain radiograph grading system for 
haemophilic arthropathy of the knee.  
          Stage 0:  normal joint. 
Stage I :  no skeletal abnormalities, soft-tissue swelling is present. 
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Stage II :  osteoporosis and overgrowth of the epiphysis, no cysts, no 
narrowing of the cartilage space. 
Stage III :  early subchondral bone cysts, squaring of the patella, widened 
notch of the distal femur or humerus, preservation of the cartilage space. 
Stage IV :  findings of stage III, but more advanced; narrowed cartilage 
space.  
Stage V :  fibrous joint contractures, loss of the joint cartilage space, 
extensive enlargement of the epiphyses with substantial disorganization of 
the joint.  
This method is sensitive in detecting early arthropathic changes, easy to 
perform, minimally invasive and ensures patient compliance. 
The data was analysed and conclusions drawn. 
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ANALYSIS OF RESULTS 
A total of 40 patients were included in the study 39 males (97.5%) and 1 female 
(2.5%). 
34 patients had haemophilia A and 6 of them were having haemophilia B. None of 
them had the rare haemophilia C. 
Figure 1  
PIE CHART SHOWING DISTRIBUTION OF HEMOPHILIA A AND B 
 
 
 
The above chart shows that majority of cases in the study had hemophilia A 
Haemophilia A
Haemophilia B
 48
Age and sex distribution is shown in table no.1 
Table no.1 – TABLE SHOWING DISTRIBUTION OF PATIENTS BASED ON  
                    AGE AND SEX 
 
 
There was only a female patient in the study and she aged 25-35 yrs. Majority were 
males of age 25-35 yrs. 
 
 
Age group 
sex 
males percentage female percentage 
15-25 yrs 13 32.5 0 0 
25-35 yrs 16 40 1 2.5 
35-45 yrs 8 20 0 0 
45-55 yrs 2 5 0 0 
 Figure 2 
 BAR DIAGRAM SHOWING DISTRIBUTION OF PATIENTS BASED ON AGE AND SEX
  
The above bar chart shows that majority of patients in the study were 
males. 
 
Only one patient was a recently detected case of 
couple of patients were diagnosed for over 30 years. Majority of patients fell in the 
category where their diagnosis was made 
 
 
 
0
5
10
15
20
15
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males
females
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Table no.2 –TABLE SHOWING DISTRIBUTION OF CASES BASED ON 
YEARS SINCE INITIAL DETECTION 
Years after diagnosis Number of  patients percentage 
 < 10yrs     1   2.5 
 10-20yrs     16   40 
 20-30yrs     21   52.5 
 >30yrs     2   5 
             In most of the patients initial diagnosis was made between 10 and 30 yrs of 
age. 
Indications of admissions were assessed and most of them had 
musculoskeletal bleeds. Some got admitted due to ent bleeds, gi tract 
bleeds, cns bleeds, genitourinary and others in the decreasing order of 
frequency. It is given in following table. 
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Table 3 – TABLE SHOWING INDICATIONS FOR IN PATIENT CARE 
OF HAEMOPHILIC PATIENTS 
 
Indication for admission Number of cases percentage 
Musculoskeletal bleed     29  72.5 
Ent bleed     5  12.5 
Gi tract bleed     2    5 
Cns bleed     2    5 
Genitourinary bleed     1   2.5 
Others      1   2.5 
 
 
The main indication of admission was for musculoskeletal bleeds. 
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Figure 3  
BAR DIAGRAM SHOWING DISTRIBUTION OF CASES BASED ON 
INDICATIONS FOR INPATIENT CARE 
 
  
The above diagram shows that most of patients were admitted with 
musculoskeletal bleeds. 
30 out 40 patients were previously admitted due to bleeding manifestations 
especially due to musculoskeletal bleeds. In fact 26 of these admissions were for 
that only 
0 5 10 15 20 25 30 35
musculoskeletal bleeds
ent bleeds
gi tract bleeds
cns bleeds
genitourinary bleed
others
number of patients
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Figure 4  
DIAGRAM SHOWING DISTRIBUTION OF CASES BASED ON PREVIOUS 
ADMISSION FOR BLEEDS 
 
The pie chart shows that 75% of patients had history of inpatient care for bleeds 
in the past.  
 
FIGURE 5 
CHART SHOWING PATIENTS WHO WERE ADMITTED WITH RECURRENT 
MUSCULOSKELETAL BLEEDS 
previously admitted
not admitted previously
  
 
 
From the above chart we can see that 26 patients had recurrent 
 
Family history was present in 10% of patients
haemarthrosis
- 4 out of 40 cases studied
previously admitted with 
haemarthrosis
not admitted previously
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Figure 6 
 DIAGRAM SHOWING DISTRIBUTION OF PATIENTS BASED ON 
PRESENCE OF FAMILY HISTORY OF HEMOPHILIA 
 
The above chart shows only few patients had positive family history. 
All admitted patients were then subjected to clinical examination to assess the joint 
involvement, irrespective of whether they were admitted for haemarthrosis or not. 
Tests were done for joint mobility and stability and any swellings either soft tissue 
or bony were noted and recorded in the proforma prepared. Also looked for the 
presence of local warmth and tenderness of the joint. 
After thorough clinical examination all 40 patients were subjected to radiological 
examination of both knee joints, as knee is the most commonly involved joint by 
family history present
family history absent
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hemophilic arthropathy. Majority of patients also underwent CT/MRI of knee joint, 
especially those with either current or previous haemarthrosis. Then with the help 
of the qualified radiologist joint pathology was categorized into various stages as 
per the Arnold-Hilgartner classification.  
The following table gives the staging of patients based on radiology 
Table-4  
TABLE SHOWING DISTRIBUTION OF PATIENTS BASED ON FINDINGS IN 
RADIOGRAPHS OF KNEE BY ARNOLD –HILGARTNER CLASSIFICATION 
Staging of joint Number of patients Percentage 
    I      1    2.5 
    II     13    32.5 
    III     23    57.5 
    IV      2    5 
    V      1    2.5 
 
Majority of patients were in stage III, 23 out of 40 which accounts for 57.5% of 
study population.  
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Figure 7 
 DIAGRAM SHOWING DISTRIBUTION OF PATIENTS BASED ON 
FINDINGS IN RADIOGRAPHS OF KNEE JOINT BY ARNOLD -
HILLGARTNER CLASSIFICATION 
 
The above bar diagram shows that majority of cases had intermediate stages of 
involvement of knee joint 
In patients with previous history of admission for musculoskeletal bleeds by way 
of clinical and radiological assay, we were able to quantify the arthropathy clearly. 
This helped both in patient education about the disease and also in management. 
0 5 10 15 20 25
stage I
stage II
stage III
stage IV
stage V
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Up to stage III disease in which there is no articular cartilage damage, patients can 
be managed conservatively.  
CT and MRI were suggested to those with stage III and above to have a look in to 
the finer details of the joint pathology. In almost all cases the findings of X-rays 
were consistent with that of CT/MRI. Early changes of hemophilic arthropathy can 
thus be detected with the help of CT/MRI.    
But in those with advanced stages of arthropathy, only solution to prevent 
permanent damage to the joint was joint replacement therapy under factor cover. 
Three of the patients with advanced hemophilic arthropathy were referred to the 
orthopaedician for decision regarding joint replacement. CT and MRI of the joints 
were taken and assessed the severity and two patients underwent joint replacement 
surgery and one is awaiting confirmation for surgery. 
Those with stage III and below were managed conservatively with factor 
replacement therapy based on body weight, analgesics and supportive measures 
like ice pack application. They were advised to follow up periodically on an out 
patient basis for early detection of worsening of arthropathy. Also highlighted the 
warning symptoms of the disease which requires admission like headache, bleed in 
to joint, muscle, or bleed from oropharynx, haematuria, haematemesis, hemoptysis 
etc 
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Figure 8  
DIAGRAM SHOWING TREATMENT GIVEN IN CASES DETECTED 
 
 The above chart shows the most patients had conservative management. 
We also noted the fact that if the duration of disease is more, the chance of 
developing advanced stage of disease is also more. Only one patient was recently 
diagnosed and he had a joint arthropathy grading of I. But those with long duration 
of disease more than 20 years and those on poor follow up were having advanced 
arthropathy when compared to those with regular follow up.   
conservative treatment
surgical treatment
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DISCUSSION 
As arthropathy is the commonest complication faced by a haemophiliac patient, its 
early detection holds the key for his or her’s better quality of life. Haemophilia 
almost always affects males and poses problems in their reproductive age group. 
As suggested by James V. Luck etal.69 the most common clinical manifestation of 
hemophilia is arthropathy secondary to recurrent hemarthroses and chronic 
synovitis. 72.5% of patients in our study were admitted for haemophilic 
arthropathy itself and rest with ent, gi tract, cns and other bleeds in the decreasing 
order of frequency.  
Fred.f.ferry et al. 70 suggested that prophylaxis with recombinant factor VIII can 
prevent joint damage and decrease the frequency of joint and other hemorrhages in 
patients with severe haemophilia disease. This also points out the need for early 
detection, admission of patients and treatment with factor replacement therapy. In 
our study 29 patients got admitted with musculoskeletal bleeds out which 18 
(62.07%) were in staging III of haemophilic arthropathy classification. Only two 
and one patients were categorized in the advanced stages IV and V respectively. 
Rest all patients were in lower stages which needed prompt treatment with factor 
replacement therapy and supportive care to halt the progression to advanced stages. 
 
  
 
As shown in these diagrams
studied 
 
 
 
 
 
FIGURE 1 DIAGRAM SHOWING DISTRIBUTION OF STAGES OF HEMOPHILIC ARTHROPATHY 
 late arthropathy was more common among the cases 
AMONG CASES
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stage III,IV & V
stage I & II
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FIGURE SHOWING STAGES OF  HEMOPHILIC ARTHROPATHY IN CASES STUDIED 
 
 
Out of 11 patients admitted with non musculoskeletal bleeds 10 of them clinically 
gave us no evidence of arthropathy. Remaining one patient had clinical arthropathy 
and stage III of haemophilic arthropathy. Out of the ten patients with no clinical 
evidence of arthropathy four were already in stage III of haemophilic arthropathy. 
So silently the have progressed to stage III without any symptoms and signs.  
 
0 2 4 6 8 10 12 14 16 18 20
stage I
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stage III
stage IV
stage V
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 DIAGRAM SHOWING DISTRIBUTION OF HEMOPHILIC ARTHROPATHY DETECTED 
RADIOLOGICALLY 
    
The management depends on the staging of arthropathy. Up to stage III 
conservative management is tried. According to v.krislo et al.  the most common 
surgical procedures71 used to manage hemophilic arthropathy are synovectomy, 
joint debridement, fusion, and joint arthroplasty. Arthroplasty and latest joint 
replacement therapy are reserved for those with permanent damage to the joint. In 
our study also we managed majority of patients conservatively and only 3 patients 
with severe joint damage and disfigurement were referred for orthopaedic 
procedures.  
0
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In our study we came to know the fact that as the duration of disease process is 
more, the risk of acquiring advanced stages of disease are more. Those with 
advanced stages of disease invariably had joint deformities despite adequate 
medical attention. As per Allen g, aledort etal.in end stage 72haemophilic 
arthropathy if adequate measures are not undertaken, the joint will almost certainly 
progress to endstage arthropathy, which is best managed by surgery (ie, total 
arthroplasty for knees and hips or arthrodesis in ankles). So two of our patients 
underwent surgery – joint replacement and one is awaiting confirmation. 
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CONCLUSION 
Haemophilia is a common coagulation disorder encountered by physicians. Males 
are almost always affected with very few exceptions. Haemophilia A is the one 
much more common than Haemophilia B. Haemophilia C is a rare coagulation 
disorder. 
The most common indication for admissions are musculoskeletal bleeds and knee 
being the commonest joint involved. Iliopsoas is the major muscle involved with 
this kind of bleed. Other bleeds like ent bleeds, gi tract bleeds, cns bleeds etc.can 
all occur in haemophiliacs. As the duration of disease process increases the risk of 
permanent joint damage also goes on the increase. 
The patients should be adequately educated about the disease. All patients with 
bleeding manifestations are treated with factor replacement therapy. All patients 
have to be screened periodically for early detection of arthropathy. Arthropathy 
staging is done as per Arnold hilgartner method. 
Those patients with early stages of arthropathy are treated conservatively with 
factor replacement therapy to halt the progression of disease. If not treated 
adequately, due to chronic synovitis permanent joint damage occurs. Once this 
happens only surgical cure is possible to restore the joint function. The various 
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modalities available are synovectomy, arthroplasty and joint replacement in severe 
cases. 
Even in haemophilics admitted for non-musculoskeletal indications arthropathy 
may lie undetected and if unnoticed can result in joint damage. So evaluation is 
needed noy only clinically but also radiologically as radiology detects it earlier. 
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Name Ag
e  
Se
x  
Ip no. Musculos
keletal 
bleed 
Ent 
bleed 
Git 
bleed 
Cns 
bleed 
Genitourinary 
bleed 
Others  Duration of 
disease 
Previous 
admissions 
Clinical 
findings 
Radiological 
staging 
Rajkumar 18 m 62123 y      b y n III 
Ravikumar 24 m 63007 y      b y n III 
Nagarj 34 m 63122  y     c y y III 
Abdul rahim 36 m 64190 y      c y y III 
Vasudevan 26 m 64298  y     b y n II 
Suresh 38 m 65289 y      c y y III 
Palanisamy 39 m 68004 y      c y y III 
Dinesh 16 m 005 y      a n n I 
Balasubramanian 29 m 178 y      c y n III 
Abdul rahman 19 m 274    y   b n n II 
Aruchamy 44 m 543 y      c y y V 
Lakshmi 28 f 678 y      c y y III 
Tyagarajan 26 m 741 y      b y n II 
Veerapandi 27 m 900 y      b y n II 
Senthil 19 m 902 y      b n n II 
Vinayakan 18 m 1378  y     b n n II 
Arumukam 46 m 1702   y    d n n III 
Govindraj 27 m 1890 y      c y n III 
Arusamy 33 m 2196 y      c y y III 
anwar 32 m 2278 y      c y n III 
Cristopher 48 m 2666  y     d y n III 
Sankar 38 m 2790 y      c y y III 
Ilangovan 18 m 3002 y      b y n II 
Marimuth 19 m 3713 y      b y n II 
Kandasami 26 m 3902 y      b y n II 
Palanisami 42 m 4123 y      c y y IV 
Rajasekar 43 m 5510   y    c n n III 
Sekar 29 m 6129 y      c y y III 
Prakasam 30 m 6782 y      c y n III 
Bharath 18 m 7921     y  b n n II 
Vivek 19 m 8829      y b n n II 
Arunachalam 28 m 9921 y      c y y III 
Vadivel 27 m 9929 y      c y y III 
Murugan 31 m 10019    y   c n n II 
Murali 40 m 10789 y      c y y IV 
Raj 24 m 12105 y      b y n III 
Sakthivel 23 m 13290 y      b y n III 
Sreedhar 31 m 14920  y     c y n III 
Anbalagan 20 m 16002 y      b n n II 
Saravanan 32 m 17003 y      c y y III 
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PROFORMA 
 
Name:                                                                                  Age / Sex:    
                                                                         
Address:                                                                                                                                                                               
                                                                                        
DOA:                                                                                   DOD:  
 
Chief complaints  
 
1. Duration of bleeding 
2. Onset of bleeding 
3. Site involved 
4. Pain or discomfort 
5. Precipitating event 
6. Progression of bleeding 
7. History suggestive of complication like headache, abdominal pain 
 
 
Past history  
 
1. H/O DM / HTN  
2. H/O TB  
3. H/O Surgery 
4. H/O previous admission and its indication 
5. H/O of factor or blood transfusion 
 
Family history  
 
1. H/O DM / HTN  
2. H/O TB 
3. H/O of haemophilia 
  
 84
Personal history  
 
1. Diet  
2. Sleep  
3. Bowel / Bladder  
4. Smoker / Alcoholic  
 
 
GENERAL PHYSICAL EXAMINATION  
 
1. Obese / Not Obese  
2. Nutritional status: Poor / Avg / Good  
3. Pallor  
4. Icterus  
5. Cyanosis / Clubbing  
6. General – Lymphadenopathy  
7. PR  
8. BP  
 
Local examination  
       Depending on the site of bleeding 
 
 
Examination ok knee joint 
 
Inspection 
1. gait 
2. attitude 
3. swelling 
4. muscular wasting 
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Palpation  
 
1. local rise of temperature 
2. local tenderness 
3. swelling 
4. popliteal fossa 
5. bony compartments 
6. wasting 
7. joint 
  
Movements  
 
Flexion and extension  
Abduction and adduction 
Rotation 
  
Measurements 
 
Length of the limb 
Inter malleolar separation 
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ABBREVIATIONS 
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ABBREVIATIONS 
 
HIV – Human Immunodeficiency Virus 
MRI – Magnetic Resonance Imaging 
CT – Computed Tomography 
FFP – Fresh Frozen Plasma 
PCCs – Prothrombin Complex Concentrates 
EACA – Epsilon Amino Caproic Acid 
DDAVP – 1-Deamino 8- D Arginine Vasopressin 
rFVIIa – Recombinant Activated Factor VII 
CNS – Central Nervous System 
GIT – Gastro Intestinal Tract 
ENT – Ear Nose Throat 
NSAIDs – Non Steroidal Anti-inflammatory Drugs 
CPPD – Calcium Pyrophosphate Deposition Disease 
RA – Rheumatoid Arthritis 
OA – Osteo Arthritis 
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CONSENT FORM 
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CONSENT FORM 
Yourself Mr/Mrs/Ms………………………………………………………….……  
are being asked to be a participant in the research study titled “A STUDY OF 
HAEMOPHILIC PATIENT’S INDICATION FOR ADMISSION 
AND EARLY DETCTION OF ARTHROPATHY” in CMC Hospital, 
Coimbatore, conducted by Dr.Unnikrishnan.S., Post Graduate Student in the 
Department of General Medicine, Coimbatore Medical College. You satisfy 
eligiblility as per the inclusion criteria. You can ask any question you may have 
before agreeing to participate. 
Research Being Done 
Indication of admission and early detectionof haemophilic arthropathy in 
Coimbatore Medical College 
Purpose of Research 
v To find the indications of admissions in haemophilia patients. 
v To detect haemophilic arthropathy at an early stage with clinical and 
radiological testing. 
Procedures involved 
The research includes detailed clinical examination including medical history, 
physical examination with reference to the indication of admission. Physical 
examination involves examination of knee joint based on movements and 
measurements. Then radiology of the knee joint is done for all patients and staging 
of arthropathy done. Only in patients with advanced staging CT/MRI of the knee 
joint may be taken.   
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Decline from Participation 
You have the option to decline from participation in the study  existing protocol for 
your condition. 
 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or provided 
by you during the study will be kept strictly confidential. 
Authorization to publish Results   
Results of the study may be published for scientific purposes and/or presented to 
scientific groups, however you will not be identified. 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the consent or it has 
been read to me. The study has been fully explained to me, and  I may ask 
questions at any time. 
 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
 
 
